Sen. Chuck Grassley recently had sharp words for not-for-profit hospitals, following a Politico investigation that looked at how hospitals have cut back on charity care since the Affordable Care Act went into effect but still reap major financial benefits by not paying federal, [...]
Today’s healthcare landscape is rapidly evolving, with many trends emerging and policy changes under consideration that have far-reaching implications for cancer care. As a medical oncologist at Texas Oncology, I have been very active in collaborating with ASCO, the Community [...]
An increasing number of cancer drugs are now delivered in oral formulations, with an estimated 25% to 35% in the research pipeline being orals. Increasingly, patients prefer to receive their oral cancer drugs and ancillary oral therapies in a safe, reliable, [...]
David Shulkin, the current U.S. Secretary of Veterans Affairs and a holdover from the Obama administration, has been interviewed by the White House for the top job at Health and Human Services, according to sources familiar with the meetings. Read [...]
As President Donald Trump signals impatience to wind down emergency aid to Puerto Rico, the challenges wrought by Hurricane Maria to the health of Puerto Ricans and the island’s fragile health system are in many ways just beginning. Read the full article [...]
Food and Drug Administration Commissioner Scott Gottlieb serves a president who regularly speaks of rolling back business regulation. Dr. Gottlieb has postponed Obama-era food-labeling rules, pleasing some food manufacturers. Read the full article on The Wall Street Journal here.
The International Brotherhood of Teamsters is taking aim at Cardinal Health Inc. in the union’s quest to demand accountability from companies it says are responsible for fueling the U.S. opioid crisis, and it’s asking other shareholders to join in. Read the full [...]
Measuring relevant outcomes in a timely manner is a priority in a health care system increasingly focused on the delivery of high-value care. Most quality measures focus on care processes or downstream outcomes such as survival; until recently, there has [...]
The Trump administration is considering rolling back an Obama-era policy that supporters say successfully lowered some prescription drug prices, but that opponents say discourages innovation. Read the full article on Stat here.
The National Institutes of Health on Thursday announced a $215 million public-private partnership with 11 pharmaceutical companies in what the agency bills as a significant next step in its cancer moonshot. Read the full article on Scientific American here.